Development of an effective vaccine for prevention of infection with HIV would provide an important mechanism for controlling the AIDS epidemic. In the current study, the first clinical trial of a candidate HIV-1 vaccine initiated in the United States, the safety and immunogenicity of escalating doses (10-1,280 micrograms) of recombinant gp160 (rgp160), were evaluated in 138 HIV-negative volunteers. Maximal antibody responses, as evaluated by ELISA, were seen after immunization with three doses of 1,280 micrograms rgp160. Responses to some specific epitopes of HIV gp160, including the second conserved domain and the CD4 binding site, were seen more frequently than after natural infection. Neutralizing antibodies to the homologous HIV strain, but not heterologous strains, were induced by this regimen. Blastogenic responses to rgp160 were seen in most volunteers receiving at least two doses of > or = 20 micrograms. These envelope-specific T cell responses were also seen against heterologous strains of HIV. No major adverse reactions were seen after immunization. Thus, rgp160 is a safe and immunogenic candidate HIV vaccine; further studies are needed to determine if it will provide any clinical benefit in preventing HIV infection. 
Introduction
Development of an effective HIV vaccine is a critical goal of the effort to control the AIDS epidemic (1) (2) (3) (4) (5) . Although a number of antiretroviral agents that are potentially effective in delaying disease progression in HIV-infected patients, such as zidovudine, have been identified, no agent has yet been identified that will effectively prevent progressive immunodeficiency and its devastating consequences (6-1 1 ). Prevention of infection or modification of the clinical course of HIV-induced disease is thus crucial to stemming the AIDS epidemic.
Developing a vaccine for HIV poses a number of problems (1, 5) . Numerous studies have demonstrated the presence of specific, potentially protective activities ofthe immune system, such as neutralizing antibodies (12) (13) (14) (15) (16) (17) (18) , cell-mediated cytotoxicity (19) (20) (21) (22) (23) , and antibody-dependent cellular cytotoxicity ( 18, (24) (25) (26) (27) (28) (29) , in individuals with HIV infection, but no study to date has convincingly demonstrated which specific immune mechanisms, if any, will protect against HIV infection or HIVinduced immunosuppression in humans. Moreover, the presence of a hypervariable region in the principal neutralizing domain as well as in other regions of the HIV outer envelope protein, gp120, has raised concerns that HIV will be able to evade the effects of neutralizing antibodies through changes in these regions ( 13-17, 30, 31 ) .
Although the challenge of developing an effective AIDS vaccine is formidable, recent studies using simian immunodeficiency virus (SIV)' infection in monkeys have demonstrated protection against challenge with SIV after immunization with whole, inactivated SIV (32) (33) (34) or a live, attenuated SIV (35) . Further, evaluation of SIV subunit vaccines has suggested that glycoprotein-enriched fractions, which include the envelope proteins, are responsible for the observed protection (36) . Although recent reports have suggested that protection in studies using whole inactivated SIV resulted from development ofantibodies to cellular components (37) (38) (39) (40) (41) , in a recent study, complete protection was conferred after immunization with recombinant vaccinia virus-expressed envelope protein followed by immunization with baculovirus-expressed protein (42) . Studies in chimpanzees have also demonstrated partial protection against HIV infection after variable immunization schemes and immunogens, including immunization with recombinant gp 120 (43) as well as combinations of whole inactivated virus, recombinant, vaccinia virus-derived, gp 160, and keyhole limpet hemocyanin (KLH)-conjugated peptides corresponding to the V3 loop of gpl20 (44) . More recently, protection of chimpanzees against challenge with cell-associated virus has been reported (45) . These studies clearly demonstrate that, in an animal model ofHIV infection or ofa disease closely related to AIDS, protective immunity can be induced by immunization and thus support the concept that protective immunity against HIV can be induced in humans. Further, a recent study using a mAb to the V3 loop of HIVIIIb demonstrated that infec- (46) . Given the urgency of the problem, in 1987 we initiated the first HIV vaccine trial in the United States, using a baculovirusexpressed recombinant gpl 60 (rgpl 60) adsorbed to alum as the immunogen (47, 48) . The goals ofthe study were to evaluate the safety of immunizing humans with the envelope of HIV; to evaluate the nature ofthe immune response that could be elicited with a recombinant HIV envelope protein; and to establish a dose-response relationship between immunogen and level of immune response. In this study, we have demonstrated that high doses of rgp 160 can be safely administered to seronegative volunteers, and that rgp 160 will induce neutralizing antibodies in a dose-dependent manner.
Methods
Immunogen. rgp 160 was generated by cloning the env gene of LAV-1, obtained from an infectious HIV clone, into an expression vector derived from the baculovirus Autographa californica Nuclear Polyhedrosis Virus (47) . Recombinant protein was produced in Lepidopteran cell cultures, purified, and adsorbed to alum (VaxSyn HIV-1; MicroGeneSys Inc., Meriden, CT) (47) . rgp 160 has a molecular weight of -160,000, is glycosylated, and exists in its purified form as a tetramer.
Initial rgp 160 preparations, used in the 10-80 Mg per dose immunizations, were > 80% pure, as estimated by densitometry of SDS-PAGE gels. Subsequent lots were > 95% pure. The final formulation contained 10-640 Mug rgp 160/ml of vaccine.
Immunization. The study was conducted in two parts. In the first part, healthy homosexual or bisexual men between the ages of 18 and 60 with no evidence of HIV infection or existing medical problems were sequentially enrolled in eight groups of 15 patients. All volunteers received an initial immunization of 10, 20, 40, 80, 160, 320, 640, or 1,280 Mg rgp 160. 10 volunteers in each group received a booster immunization at 1 mo; five received one half the original immunizing dose, and 5 received the full immunizing dose. Three additional volunteers received 80 Mg followed by a full-strength boost when a new vaccine lot was used. A subgroup of volunteers receiving 2 160 Mg who had received a 1-mo boost were eligible for additional full-strength booster immunizations at 6, 12-18, and 18-24 mo.
In the second part, designed to examine the specificity of the response, volunteers were randomized in a double-blind fashion to immunization with either rgp 160 or KLH, each at a dose of 320,ug. Fullstrength booster immunizations were administered at 1 and 6 mo. 10 homosexual or bisexual men and 5 heterosexual men participated in this phase.
All immunizations were administered into the deltoid muscle. Volunteers were seen in clinic weekly for 1 mo after the initial immunization and then monthly. At each visit, a brief history, including possible reactions to immunization, was elicited and blood was obtained for evaluation of safety and immune responses.
Laboratory assays. To detect antibody responses to specific HIV proteins, sera (1:100) were evaluated using a commercial immunoblot kit (DuPont Co., Wilmington, DE). Reactivity with individual bands was scored as positive if any reactivity with that band was visualized. Antibody responses were quantitated by ELISA, using a commercial kit (Abbott Laboratories, Abbott Park, IL). ELISA results were compared with a standard curve generated using a control serum from an HIV-infected patient and are expressed as units, with 1 U being defined as the amount of antibody present in a 1:2,100,000 dilution of the control serum.
Antibody responses to specific epitopes were determined by immunoblot, using purified Escherichia coli malE-gp160 epitope fusion proteins as previously described (48) (14, 16) , the immunodominant domain of gp4l (579-605) (52) , and a putative neutralizing region in gp4l (735-752) (53) . The epitope blots were incubated with a 1: 1,000 dilution ofprimary serum overnight at room temperature, washed, and incubated for 1 h at room temperature with alkaline phosphatase-conjugated goat anti-human IgG. Epitope responses were quantitated by ELISA, using serial twofold dilutions of sera, starting at 1:50. Plates were coated with purified epitope fusion proteins or rgp 160 at 100 ng per well. The end point titer was defined as the titer that gave an OD . 0.05, which was also at least fourfold higher than the mean OD of pooled normal human serum.
Neutralization was determined using an MT2 cell assay (54 For blastogenic assays, peripheral blood mononuclear cells were obtained by Ficoll-Hypaque density gradient centrifugation and either assayed immediately or cryopreserved to allow simultaneous assay of sequential samples from the same volunteer. Proliferative responses to rgpl60 (MicroGeneSys, Inc.) at concentrations of 10, 5, or 1 gg/ml were determined in microtiter plates in triplicate using standard techniques (56) . During the early part ofthe study, blastogenic responses to baculovirus proteins alone served as a control for responses to contaminating proteins. After demonstrating a lack of response to baculovirus proteins, subsequent assays used serum controls. Recombinant envelope proteins from HIVNy5 (57) and SIV,,251 (33) were expressed and purified to > 95% using the same procedures as for rgpl6O vaccine. CD4 and CD8 counts were determined by FACS analysis using standard techniques (56) .
The protocol was approved by the institutional review board of the NIAID and all volunteers provided written informed consent after the risks of the study had been explained. O t03D c°o3 cmn O 320cg primary immunization. Reactivity by immunoblot was initially to gp160 and gp 120. Antibodies to gp41 were seen only after the second booster immunization, even in the 1,280-Lg group. In addition, reactivity was also seen with a band with a molecular weight 88,000 (Fig. 1) , a previously uncharacterized band also seen on immunoblots when using serum from patients infected with HIV-1, which thus is presumably an envelope-related protein.
Quantitation of antibody responses by ELISA for the 18 patients in the 160-1,280-,tg groups who received five immunizations are summarized in Fig. 2 a. Near maximal responses were seen in the 640-and 1,280-,ug groups after three immunizations; similar responses were seen in the 160-and 320-.ug groups after four immunizations. Although titers fell between immunizations, there was a rapid anamnestic response after rechallenge. In six patients in the 640-and 1,280-,gg group, antibody responses after the fifth immunization were measured more frequently; peak responses were seen within 2 wk in most patients and declined to 50% maximal levels by 8 wk after immunization (Fig. 2 b) . To identify specific epitopes against which antibodies were induced, immunoblot studies using recombinant fusion proteins containing functionally important epitopes ofgp 160 were performed after four immunizations (Table II and Fig. 3 Neutralization of the LAV isolate of HIV was evaluated using one to three serum samples obtained 31-83 wk after initial immunization from the 11 volunteers that showed maximal ELISA reactivity. None ofthe six volunteers in the 320-or 640-,ig groups who were tested developed neutralizing antibodies. Four of five volunteers in the 1,280 ,g group developed neutralizing titers of 1:4-1:8 compared with neutralizing titers of 1:16-1:256 seen in HIV-infected patients (Fig. 4) . End point dilution titers to specific epitopes were determined by ELISA; all three volunteers with titers of 1:400 to the V3 loop showed neutralizing antibodies, whereas only one volunteer with a lower titer had neutralizing activity (Table III) Fig. 5 a  (top) . Blastogenic responses were also seen to rgp 160 derived from a heterologous HIV isolate (HIVNY-5) but not from SIV (Fig. 5 b) .
Among the randomized patients in the second part of the study, an antibody response similar to that seen in the 320-,ug (Fig. 5 a, bottom) .
Immunization with rgp160 was well tolerated. The most common side effects attributable to immunization included local soreness and redness at the site of immunization, fever, and flu-like symptoms (Table IV) End point dilution titers to epitopes ofgp 160 for sera from 11 volunteers immunized with rgp 160. Serial twofold dilutions of sera, starting at 1:50, were evaluated by ELISA using plates coated with purified epitope fusion proteins or rgp 160 at 100 ng per well. The end point titer was defined as the titer that gave an OD 2 0.05, which was also at least fourfold higher than the mean OD of pooled normal human serum. Weeks indicates time after primary immunization. Neutralization titers are for the same sample.
prothrombin time that normalized after parenteral administration of vitamin K. 5 mo after the initial immunization, a third volunteer (320-Ag group) developed left-sided weakness and numbness, a tremor, and an episode of blurred vision, which was diagnosed as multiple sclerosis. In retrospect he had similar visual symptoms 6 yr before immunization. Concerns about the potential toxicity of HIV envelope protein to CD4 cells have been raised ( 1, 58, 59) . In this study, no immunologic changes were seen after immunization with rgpl 60. Specifically, no significant changes in CD4 or CD8 number were seen. CD4 and CD8 values for the 1,280-ug group during 1 yr of follow-up are shown in Fig. 6 , top. Additionally, no changes in natural killer cell activity or in blastogenic responses to tetanus toxoid or phytohemagglutinin were seen (data not shown). Among the patients randomized to KLH or gp 160, no significant differences were seen among the groups in any of the laboratory parameters evaluated, including the immune parameters. The changes in CD4 counts for these two groups are shown in Fig. 6 
Discussion
This study has clearly demonstrated that rgpl 60 is a safe and immunogenic vaccine candidate that is capable of inducing neutralizing antibodies as well as blastogenic responses in a dose-dependent manner, with the optimal immunizing regimen being three doses of 1,280 ,g rgp 160 administered at 0, 1, and 6 mo. This regimen will induce a sustained blastogenic response as well as antibodies that decline in titer over the course of a year but that can rapidly be reinduced. Although the current vaccine preparation clearly is immunogenic, the degree of protection conferred will ultimately be determined only by a randomized trial. Immunization with the rgpl60 preparation used in this study has also been shown to induce new humoral and cell-mediated responses in patients with HIV infection, responses which may be associated with immunologic stabilization (48) .
The latter study suggests that a major advantage of rgp 160 is the unique presentation, compared with naturally acquired infection, of potentially important envelope epitopes. In this study we have shown that HIV-seronegative volunteers will also develop antibodies to these epitopes with a greater frequency than is seen in naturally acquired infection. Which of these epitopes, if any, are important in inducing protection against infection is unknown at present, and it is possible that antibodies to these epitopes have no clinical significance. Our data support the suggestion, however, that development of anti-V3 antibodies after immunization is associated with neutralization of the homologous viral isolate, and at least one study has shown that an anti-V3 neutralizing mAb can prevent HIV infection (46) . Neutralizing titers were lower than seen in naturally acquired infection; however, the level of neutralizing antibodies needed for protection ofHIV-negative individuals is currently unknown. Although the current rgp 160 This may be because of differences in study population or, more likely, in the assay technique used for measuring neutralization.
In studies of SIV vaccines efficacy was demonstrated despite induction of only low levels of neutralizing antibodies when compared with levels induced after infection with SIV (32) (33) (34) . Although protection in many of these studies appears to have depended on the development of anticellular antibodies (37) (38) (39) (40) (41) , one report has demonstrated protection after immunization with recombinant subunit envelope vaccines (42) .
Blastogenic responses to gp160 were induced earlier and by lower doses of rgp 160 than were necessary for antibody induction. Although small amounts of baculovirus-derived proteins may have contaminated the immunogen, the proliferative responses were specific for gp 160 and not contaminating proteins, because no blastogenic response was seen to baculovirus proteins alone in patients showing proliferative responses to gpl 60. Additionally, patients showed proliferation to recombinant HIV-derived envelope proteins but not identically prepared SIV-derived proteins. Finally, blastogenic responses were also seen to vaccinia-generated HIV envelope proteins, which contained no baculovirus products (data not shown).
Although no other studies have used doses of rgp 160 as high as those used in the current study, other investigators have also found blastogenic responses after immunization with low doses of rgp 160 (60-63). Furthermore, in characterizing these T cell responses, CD4 positive, but not CD8 positive, cytolytic T cells specific for HIV have been identified and cloned, and a conserved T cell epitope in gp4 1 has been shown to be recognized by some of these clones (64) (65) (66) . Immunization has also been associated with T helper responses, as shown by IL-2 production, to envelope-derived peptides. Thus, immunization with rgp 160 can induce potentially beneficial cell-mediated immune responses.
A major goal of this study, the first vaccine trial initiated in the United States, was to demonstrate the safety and the immunogenicity of a candidate HIV vaccine, thus providing strong support for the initiation of further vaccine trials in both seronegative and seropositive individuals (47, 48) . No adverse events other than those commonly seen after immunization with other vaccine preparations were attributable to rgp 160. Specifically, there was no evidence of an immunosuppressive effect of rgp 160, even after five immunizations with the highest dose used in this trial.
Given the urgency of developing an effective vaccine and the demonstrated safety and immunogenicity of rgpl60, phase II trials of rgp 160 (genetically engineered to resemble endemic strains) as well as of other candidate HIV vaccines should proceed quickly and should be expeditiously followed by randomized, blinded phase III trials of the most promising candidate vaccine(s). Such trials are needed to define the true clinical utility of vaccine preparations. In this regard, utility can be defined not only as a vaccine that can prevent infection but also one that can slow the rate of progression after infection. Although the immune mechanisms needed for protection against HIV have not yet been identified, delaying efficacy trials until protective mechanisms have been clearly elucidated is not warranted, because these mechanisms may not be defined for many years. This study, as well as others evaluating potential HIV vaccine candidates (47, (67) (68) (69) (70) , have established the feasibility of proceeding to randomized trials, and definitive establishment of efficacy will ultimately be provided only by such a trial. 
